Literature DB >> 19054791

A humanized anti-M2 scFv shows protective in vitro activity against influenza.

J Gabbard1, N Velappan, R Di Niro, J Schmidt, C A Jones, S M Tompkins, A R M Bradbury.   

Abstract

M2 is one of the most conserved influenza proteins, and has been widely prospected as a potential universal vaccine target, with protection predominantly mediated by antibodies. In this paper we describe the creation of a humanized single chain Fv from 14C2, a potent monoclonal antibody against M2. We show that the humanized scFv demonstrates similar activity to the parental mAb: it is able to recognize M2 in its native context on cell surfaces and is able to show protective in vitro activity against influenza, and so represents a potential lead antibody candidate for universal prophylactic or therapeutic intervention in influenza.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19054791     DOI: 10.1093/protein/gzn070

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  14 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

2.  Selection of phage-displayed accessible recombinant targeted antibodies (SPARTA): methodology and applications.

Authors:  Sara D'Angelo; Fernanda I Staquicini; Fortunato Ferrara; Daniela I Staquicini; Geetanjali Sharma; Christy A Tarleton; Huynh Nguyen; Leslie A Naranjo; Richard L Sidman; Wadih Arap; Andrew Rm Bradbury; Renata Pasqualini
Journal:  JCI Insight       Date:  2018-05-03

3.  A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.

Authors:  Pierre-Louis Hervé; Mariam Raliou; Christiane Bourdieu; Catherine Dubuquoy; Agnès Petit-Camurdan; Nicolas Bertho; Jean-François Eléouët; Christophe Chevalier; Sabine Riffault
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

4.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

5.  Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo.

Authors:  Sweety Samal; Tripti Shrivastava; Praveen Sonkusre; Zaigham Abbas Rizvi; Rajesh Kumar; Shubbir Ahmed; Preeti Vishwakarma; Naveen Yadav; Manish Bansal; Kanchana Chauhan; Sebanta Pokhrel; Supratik Das; Padmakar Tambare; Amit Awasthi
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

6.  Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge.

Authors:  Leo K Sage; Julie M Fox; Andrew L Mellor; Stephen M Tompkins; Ralph A Tripp
Journal:  Viral Immunol       Date:  2014-04-04       Impact factor: 2.257

7.  Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.

Authors:  Lynn Bimler; Sydney L Ronzulli; Amber Y Song; Scott K Johnson; Cheryl A Jones; Teha Kim; Duy T Le; S Mark Tompkins; Silke Paust
Journal:  J Virol       Date:  2020-12-02       Impact factor: 6.549

8.  Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.

Authors:  Mohamed Elaish; John M Ngunjiri; Ahmed Ali; Ming Xia; Mahmoud Ibrahim; Hyesun Jang; Jagadish Hiremath; Santosh Dhakal; Yosra A Helmy; Xi Jiang; Gourapura J Renukaradhya; Chang-Won Lee
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

9.  Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design.

Authors:  Denise A Kaminski; F Eun-Hyung Lee
Journal:  Front Immunol       Date:  2011-12-16       Impact factor: 7.561

Review 10.  Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.

Authors:  Nicola Clementi; Elena Criscuolo; Matteo Castelli; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Viruses       Date:  2012-11-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.